ReviewThe Journal of antibiotics2017
Development of new polymyxin derivatives for multi-drug resistant Gram-negative infections.
Review in The Journal of antibiotics, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed, 97 citations in OpenAlex.
- Adenylation Domain Engineering Enables Biosynthesis of an Improved Polymyxin Antibiotic.Angewandte Chemie (International ed. in English) · 2026Article
- HighFold4: extending AlphaFold3 to accurate cyclic peptide conformation prediction via custom chemical connectivity.Briefings in bioinformatics · 2026Article
- Lipopeptide Engineering: From Natural Origins to Rational Design Against Antimicrobial Resistance.Antibiotics (Basel, Switzerland) · 2026Review
- Paenibacillus wuxiensis sp. nov., a Novel Bacterium Capable of Producing Indole-3-Acetic Acid (IAA) and Inhibiting Rhizoctonia solani Kühn Isolated from Agricultural Soil.Current microbiology · 2025Article
- An update on novel taxa and revised taxonomic status of bacteria isolated from aquatic host species described in 2022-2023.Journal of clinical microbiology · 2024Review
- Dextrin conjugation to colistin inhibits its toxicity, cellular uptake and acute kidney injuryRSC pharmaceutics · 2024Article
- Recent Advances in the Development of Polymyxin Antibiotics: 2010-2023.ACS infectious diseases · 2024Review
- LL-37: Structures, Antimicrobial Activity, and Influence on Amyloid-Related Diseases.Biomolecules · 2024Review
- Enhancement of polymyxin B1 production by an artificial microbial consortium ofSynthetic and systems biotechnology · 2024Article
- Structures, Interactions and Activity of the N-Terminal Truncated Variants of Antimicrobial Peptide Thanatin.Antibiotics (Basel, Switzerland) · 2024Article
- Semisynthetic polymyxins with potent antibacterial activity and reduced kidney cell toxicity.RSC medicinal chemistry · 2023Article
- Scope and Limitations of Exploiting the Ability of the Chemosensitizer NV716 to Enhance the Activity of Tetracycline Derivatives againstMolecules (Basel, Switzerland) · 2023Article
- Article
- Discovery and Characterization of Polymyxin-Resistance GenesMicrobiology spectrum · 2023Article
- Antibiotic Susceptibility Testing with Raman Biosensing.Antibiotics (Basel, Switzerland) · 2022Review
- Polymyxin Stereochemistry and Its Role in Antibacterial Activity and Outer Membrane Disruption.ACS infectious diseases · 2022Article
- Synthesis and Evaluation of Polymyxins Bearing Reductively Labile Disulfide-Linked Lipids.Journal of medicinal chemistry · 2022Article
- Next-Generation Polymyxin Class of Antibiotics: A Ray of Hope Illuminating a Dark Road.Antibiotics (Basel, Switzerland) · 2022Review
- Serendipitous Discovery of a Highly Active and Selective Resistance-Modifying Agent for Colistin-Resistant Gram-Negative Bacteria.ACS omega · 2022Article
- A synthetic lipopeptide targeting top-priority multidrug-resistant Gram-negative pathogens.Nature communications · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Over the last decade, there has been a resurgence of interest in polymyxins owing to the rapid rise in multi-drug resistant Gram-negative bacteria against which polymyxins offer a last-resort treatment. Although having excellent antibacterial activity, the clinical utility of polymyxins is limited by toxicity, especially renal toxicity. There is much interest therefore in developing polymyxin analogues with an improved therapeutic index. This review describes recent work aimed at improving the activity and/or reducing the toxicity of polymyxins. Consideration to providing activity against emerging strains with reduced susceptibility to polymyxins is also made.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.